B

Bristol Myers Squibb

Makes drugs for cancer, blood and immune diseases

Executive Director - Multiple Teams

Full-TimeUpdated on 10/23/2026Deadline 11/30/26
$263.5k - $319.3k+ Discretionary incentive cash + Stock opportunities
Expert
PhD
Cambridge, MA, USA
HybridPreferred location is Cambridge, MA; remote arrangements may be considered case by case. Travel is approximately 30%, domestic and international.
Biology & Biotech
Company Historically Provides H1B Sponsorship

About the job

Requirements
  • A PhD or equivalent advanced scientific training in cancer biology, hematology, immuno-oncology, or a related discipline relevant to malignant diseases.
  • At least 10 years of drug discovery and/or early development experience in the pharmaceutical or biotechnology industry, with deep hands-on expertise in oncology and/or hematology.
  • Strong understanding of hematologic malignancy and solid tumor biology, with the ability to assess external opportunities against BMS Research priorities.
  • Demonstrated ability to evaluate external scientific opportunities, including academic collaborations, biotech partnerships, platform technologies, and pre-IND or IND-stage assets.
  • Experience shaping external collaboration plans—including scientific objectives, work plans, milestones, governance structures, decision points, and success measures—and negotiating them with external partners.
  • Ability to represent Hematology-Oncology external innovation and the broader Integrative Sciences mission to internal and external stakeholders.
  • Track record of advancing therapeutic programs toward IND stage or beyond, with knowledge of the scientific, translational, and operational requirements for decision-ready programs.
  • Experience working across Research, Early Development, Business Development, Alliance Management, Legal, IP, Finance, Thematic Research Centers, and Therapeutic Area leadership, or equivalent cross-functional structures, to support disciplined opportunity triage and execution.
  • Capability in building productive relationships, setting clear expectations, and keeping collaboration structures scientifically focused and operationally accountable.
  • Understanding of the financial, legal, contractual, and geographic considerations that affect external research collaborations, including non-U.S. partnerships.
Responsibilities
  • Communicate internal Hematology-Oncology Research pipeline priorities to Integrative Sciences and align external search, evaluation, and triage activities with BMS Research principles and Enterprise Hematology-Oncology Therapeutic Area strategy.
  • Lead the Hematology-Oncology triage process within Integrative Sciences, ensuring disciplined, criteria-driven evaluation of external opportunities.
  • Identify, evaluate, and bring forward hematology-oncology opportunities—including academic collaborations, biotech partnerships, platform technologies, and pre-IND or IND-stage assets—that add to or complement the internal pipeline.
  • Form and lead cross-functional diligence teams to evaluate Integrative Sciences collaboration opportunities, and provide expert scientific opinion during Business Development reviews and due diligence.
  • Partner with Search & Evaluation and Business Development transaction leads to advance prioritized opportunities on disciplined, accelerated timelines.
  • Work with Research Finance to ensure activities are aligned, captured, and approved within Research budgets.
  • Contribute to the design and execution of a blended external innovation strategy spanning corporate and academic collaborations.
  • Shape opportunities into practical collaboration plans with clear scientific objectives, work plans, milestones, governance structures, decision points, and success measures.
  • Advise on collaboration structures and contract development as the scientific lead, working with Business Development, transaction leads, Legal, and IP.
  • Serve on joint governance committees and oversight bodies established to coordinate agreed research plans with academic and industry partners, ensuring collaborations remain scientifically focused and operationally accountable.
  • Represent Integrative Sciences, as appropriate, to other BMS organizations, regulatory agencies, investors, partners, and the broader scientific community.
  • Communicate regularly to internal client and partner groups and their leadership on external research activities and progress.
  • Compose progress reports and decision documentation for senior management, and deliver presentations and briefings on scientific and organizational activities within the area of responsibility.
  • Model scientific leadership, collaborative behavior, and an enterprise mindset across Research and Integrative Sciences, consistent with BMS values.
  • Participate in Site Leadership teams where appropriate.
  • Serve as a Board Observer or in other relevant governance roles for external hematology-oncology companies on behalf of BMS, where appropriate.

About the company

Bristol Myers Squibb discovers, develops and sells prescription medicines for serious illnesses, including cancer, blood disorders, immune diseases and heart disease, for patients treated by doctors and hospitals around the world. Its best-known drug is Opdivo, an immunotherapy that helps the body's own immune system find and attack many kinds of cancer. Researchers develop drug candidates in its labs or bring them in through acquisitions and partnerships, then test them in clinical trials to win regulatory approval. The company makes and markets the approved medicines and earns its revenue from sales of patent-protected drugs. Its roots go back to a business founded in 1887, and it is based in Lawrence Township, New Jersey.

Company Size

10,001+

Company Stage

IPO

Headquarters

Lawrence Township, New Jersey

Founded

1887

Get referred to Bristol Myers Squibb

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Sales are beating forecasts: BMS raised 2026 revenue guidance to $49 billion to $50 billion in July 2026.
  • Newer drugs carry the business: they made $7.6 billion of $13.0 billion in sales in the June 2026 quarter.
  • Manufacturing careers are expanding: a $2.3 billion Houston campus announced in August 2026 will add nearly 500 skilled roles.

What critics are saying

  • Job security is shaky: BMS added 265 New Jersey layoffs in September 2026, bringing its 2026 state cuts to 718.
  • A patent cliff looms: Eliquis and Opdivo, its two biggest drugs, lose US exclusivity around 2028.
  • Older drugs are shrinking fast: Revlimid sales fell 49% to $425 million in the June 2026 quarter as generics spread.

What makes Bristol Myers Squibb unique

  • BMS owns a psychiatry first: Cobenfy treats schizophrenia without blocking dopamine, unlike antipsychotics used for decades.
  • Its top seller is shared: BMS splits Eliquis blood thinner profits roughly equally with Pfizer in most markets.
  • BMS reengineers patients' own immune cells: it sells two CAR T therapies, Breyanzi and Abecma, for blood cancers.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Flexible Work Hours
  • Hybrid Work Options
  • Professional Development Budget

Growth & Insights and Company News

6 month growth

8%

1 year growth

7%

2 year growth

7%
Yahoo Finance
Oct 23rd, 2026
Three defensive stocks to buy as AI selloff hits: BMY, Colgate and Gilead offer dividends

As investors question the costs and returns of the AI boom, some are turning to defensive stocks in healthcare and consumer goods. Three that pay quarterly dividends stand out: Bristol Myers Squibb, Colgate-Palmolive, and Gilead Sciences. Bristol Myers Squibb shares are up 14.3% this year, with a forward dividend yield of 4.3% and 18 straight years of increases. Second-quarter revenue reached $13 billion, with newer products making up nearly 60%. Colgate-Palmolive is up 20.2% this year and has raised its dividend for 64 years in a row. It reported second-quarter revenue of $5.36 billion. Gilead shares have gained 26%, against 13% for the S&P 500. Second-quarter HIV sales rose 12% to $5.7 billion.

Market Chameleon
Oct 19th, 2026
Bristol Myers to bring 12 oral presentations and nearly 60 oncology disclosures to ESMO 2026.

Bristol Myers to bring 12 oral presentations and nearly 60 oncology disclosures to ESMO 2026. 19 October 2026, 8:50 AM By Market Chameleon Produced with AI assistance and reviewed by Market Chameleon staff. Bristol Myers Squibb (BMY) said it will present new data across its oncology portfolio and pipeline at the European Society for Medical Oncology (ESMO) 2026 Congress (October 23-27 in Madrid), spanning 12 oral presentations and nearly 60 disclosures. The company's update spotlights multiple modalities across solid tumors, including late-breaking Phase 3 studies for izalontamab brengitecan (iza-bren) and late-breaking global Phase 2 data for pumitamig, alongside long-term survival results for Opdivo plus Yervoy. ESMO 2026 presence emphasizes late-breaking Phase 3 and Phase 2 catalysts across solid tumors. In the announcement, Bristol Myers highlighted two late-breaking, Phase 3 studies of izalontamab brengitecan (iza-bren), described as a potential first-in-class EGFR x HER3 bispecific antibody-drug conjugate (ADC), in EGFR-mutated non-small cell lung cancer (PANKU-Lung01) and HR+/HER2- breast cancer (PANKU-Breast01).

Savills
Oct 14th, 2026
San diego Q3 2026 life sciences market report.

San diego Q3 2026 life sciences market report. 14 October 2026 Market highlights. * Overall vacancy increased 60 basis points year over year to 28.5% in Q3 2026, up from 27.9% in Q3 2025. The increase was driven by direct vacancy, which rose to 25.8%, while sublease vacancy declined to 2.8%. * Venture capital funding slowed considerably in 2026, with $1.4 billion raised across 113 deals through Q3, down 34.1% year over year and marking the lowest Q1 through Q3 total since 2022. * Alexandria Real Estate delivered a 427,000-square-foot R&D hub for Bristol Myers Squibb at Campus Point, establishing the company as an anchor tenant at the 2.9- million-square-foot life sciences campus.

Yahoo Finance
Oct 13th, 2026
Eli Lilly beats Bristol Myers Squibb on growth: $65.2B revenue, 45% rise vs. $48.2B

A comparison of Bristol Myers Squibb and Eli Lilly concludes that Lilly is the better healthcare stock to buy in 2026, even at a premium. Lilly's 2025 revenue rose about 45% to $65.2 billion, with net income near $21 billion. Bristol Myers' revenue slipped 0.2% to $48.2 billion, though it returned to a net income of $7.1 billion after an $8.9 billion loss in 2024. Lilly trades at 33.8 times forward earnings against 8.2 times for Bristol Myers. The article says Bristol Myers is cheap for good reason, citing pricing pressure, patent expiries, and an unpredictable recovery. Lilly's weight-loss drugs Zepbound and Mounjaro are expected to lift 2026 revenue above 30%, to $88.6 billion. Bristol Myers is forecast to grow 3% to $49.9 billion.

Chinese LGZ
Oct 9th, 2026
Bristol Myers Squibb unveils $2.3 billion investment in cutting-edge Houston pharma facility.

Bristol Myers Squibb unveils $2.3 billion investment in cutting-edge Houston pharma facility. Source link: https://houston365.info/2026/10/09/bristol-myers-squibb-unveils-2-3-billion-investment-in-cutting-edge-houston-pharma-facility/ Bristol Myers Squibb strengthens Houston's life sciences sector with $2.3 billion facility. Bristol Myers Squibb is set to transform Houston's pharmaceutical landscape through a landmark $2.3 billion investment in a cutting-edge manufacturing plant. This initiative, developed in collaboration with the Greater Houston Partnership, aims to elevate the company's production capabilities while cementing Houston's status as a burgeoning center for biopharmaceutical innovation. The project is projected to generate hundreds of skilled jobs and stimulate substantial economic growth within the region. Project overview and strategic importance. The new facility will incorporate the latest manufacturing technologies to optimize efficiency and product quality. With over 1,200 new roles anticipated in scientific research, engineering, and production, the plant will serve as a catalyst for workforce development and community engagement. This expansion aligns with Bristol Myers Squibb's vision to accelerate the delivery of novel therapies and reinforces Houston's growing influence in the life sciences ecosystem. * Innovative manufacturing processes: Adoption of advanced automation and quality control systems. * Employment opportunities: Creation of more than 1,200 specialized jobs across multiple disciplines. * Community collaboration: Strengthening partnerships with local universities and healthcare institutions to foster innovation. | Investment Detail | Information | | Total... | - - Author: Samuel Brown Publish date: 2026-10-09 15:23:00 Copyright for syndicated content belongs to the linked Source. - - 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8